175 related articles for article (PubMed ID: 36894319)
1. In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A
Ohno Y; Suzuki M; Asada H; Kanda T; Saki M; Miyagi H; Yasunaga M; Suno C; Iwata S; Saito JI; Uchida S
Mol Pharmacol; 2023 Jun; 103(6):311-324. PubMed ID: 36894319
[TBL] [Abstract][Full Text] [Related]
2. Anti-parkinsonian activity of the adenosine A
Ohno Y; Okita E; Kawai-Uchida M; Fukuda N; Shoukei Y; Soshiroda K; Yamada K; Kanda T; Uchida S
Eur J Pharmacol; 2023 Jul; 950():175773. PubMed ID: 37146707
[TBL] [Abstract][Full Text] [Related]
3. The Pharmacological Potential of Adenosine A
Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.
Yamada K; Kobayashi M; Shiozaki S; Ohta T; Mori A; Jenner P; Kanda T
Psychopharmacology (Berl); 2014 Jul; 231(14):2839-49. PubMed ID: 24488405
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacological profile of the A2A receptor antagonist istradefylline.
Saki M; Yamada K; Koshimura E; Sasaki K; Kanda T
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):963-72. PubMed ID: 23812646
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
8. The belated US FDA approval of the adenosine A
Chen JF; Cunha RA
Purinergic Signal; 2020 Jun; 16(2):167-174. PubMed ID: 32236790
[TBL] [Abstract][Full Text] [Related]
9. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
10. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
[TBL] [Abstract][Full Text] [Related]
12. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
13. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Müller T
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
[TBL] [Abstract][Full Text] [Related]
14. The adenosine A
Ohno Y; Okita E; Kawai-Uchida M; Shoukei Y; Soshiroda K; Kanda T; Uchida S
J Pharmacol Sci; 2023 Jul; 152(3):193-199. PubMed ID: 37257947
[TBL] [Abstract][Full Text] [Related]
15. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.
Hauser RA; Schwarzschild MA
Drugs Aging; 2005; 22(6):471-82. PubMed ID: 15974638
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
18. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of five-membered heterocyclic derivatives of istradefylline with comparable pharmacological activity.
Wang Y; Wang H; Xu H; Zheng Z; Meng Z; Xu Z; Li J; Xue M
Chem Biol Drug Des; 2022 Oct; 100(4):534-552. PubMed ID: 35569008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
